Jerusalem, Israel

Shabtay Dikstein

This inventor holds 12 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Topical Pharmaceutical Compositions. Top assignees: Resdevco Research and Development Co. Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Resdevco Research and Development Co. L. Active years: 1979-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shabtay Dikstein. Retrieved from https://idiyas.com/inventor/shabtay-dikstein

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 12 

% Patents Active = 100.0


 

Average Co-Inventor Count = 1.3

ph-index = 6

Forward Citations = 258(Granted Patents)


Company Filing History:


Years Active: 1979-2022

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Eye Drops
Topical Compositions
Irritation Treatment
Mucous Membranes
Non-Newtonian Rheology
Cholecalciferol
Tetrahydrocannabinol
Pinene Derivatives
Dry Nose Syndrome
Surface Properties
Conjunctivochalasis
Skin Irritation
12 patents (USPTO):Explore Patents

Title: Shabtay Dikstein: Innovator in Ophthalmic Treatments

Introduction

Shabtay Dikstein is a prominent inventor based in Jerusalem, Israel. He has made significant contributions to the field of ophthalmology, particularly in the development of innovative treatments for eye conditions. With a total of 12 patents to his name, Dikstein's work has the potential to improve the quality of life for many individuals suffering from eye-related issues.

Latest Patents

Dikstein's latest patents focus on eye drops designed for the treatment of irritation not due to infection. One notable patent describes a method for treating irritation or damage to corneal or conjunctival epithelial cells, especially in cases of severe Sjögren's syndrome. This method involves applying a topically aqueous solution of glycerol with a concentration greater than 1% (w/v), with a preferred concentration of 2.5% (w/v). Remarkably, this treatment remains effective even in instances of very low tear formation, and its efficacy cannot be solely attributed to the known humectant effect of glycerol.

Career Highlights

Throughout his career, Shabtay Dikstein has worked with various organizations, including Resdevco Research and Development Company. His innovative approaches and dedication to research have positioned him as a key figure in the development of new ophthalmic treatments.

Collaborations

Dikstein has collaborated with notable individuals in the field, including Raphael Mechoulam and Naphtali Lander. These partnerships have further enriched his research and contributed to the advancement of his inventions.

Conclusion

Shabtay Dikstein's contributions to ophthalmology through his innovative patents demonstrate his commitment to improving eye health. His work continues to pave the way for new treatments that can significantly benefit patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…